Últimas noticias sobre Tenet Healthcare (NYSE:THC) Bolsa

TENET HEALTHCARE CORP

Tenet Healthcare

Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.

Downgrades

Markets

LOGI

Analistas ajustan calificaciones: Logitech pasa a Neutral, Ford baja a Underperform. Descubre las razones y los nuevos precios objetivo.

Wall Street ajusta calificaciones: Logitech, Ford y más nombres destacados

Tenet Healthcare Corporation Common Stock

Tenet Healthcare Corp

THC BIOMED INTL LTD ORD by THC BioMed Intl Ltd.

THC Biomed International Ltd

TH International Limited - Ordinary shares

TH International Ltd

THUNDER BRDG CAP PARTNERS IV INC CL A

THUNDER BRDG CAP PARTNERS IV INC UNIT 1 CL A & 1/5 WT EXP

THUNDER BRDG CAP PARTNERS IV INC WT EXP

THC THERAPEUTICS INC by THC Therapeutics, Inc.

THC Therapeutics Inc

Spinnaker ETF Series Cannabis ETF

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Craig Hettenbach initiated coverage on Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with an Overweight rating and announced a price target of $165. Tenet Healthcare shares closed at $130.78 on Tuesday. <a href="https://www.benzinga.com/quote/THC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>China Renaissance analyst Yiwen Zhang initiated coverage on Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy rating and announced a price target of $740. Spotify shares closed at $615.88 on Tuesday. <a href="https://www.benzinga.com/quote/SPOT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Jeff Schmitt initiated coverage on StoneX Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNEX#NASDAQ">SNEX</a>) with an Outperform rating. StoneX Group shares closed at $81.61 on Tuesday. <a href="https://www.benzinga.com/quote/SNEX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Anthony Trainor initiated coverage on Shake Shack Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with an Equal-Weight rating and announced a price target of $95. Shake Shack shares closed at $95.39 on Tuesday. <a href="https://www.benzinga.com/quote/SHAK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Laura Prendergast initiated coverage on Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>) with an Outperform rating and announced a price target of $5. Erasca shares closed at $1.48 on Tuesday. &nbsp;<a href="https://www.benzinga.com/quote/ERAS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SPOT stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44492633/jim-cramer-palantir-is-a-winner-recommends-selling-this-tech-stock">Jim Cramer: Palantir Is A &#8216;Winner,&#8217; Recommends Selling This Tech Stock</a></li>
</ul>
Image: Shutterstock

News

Initiation

Analyst Ratings

Trading Ideas

ERAS

SHAK

SNEX

SPOT

This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

During the last three months, 5 analysts shared their evaluations of Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Tenet Healthcare and provided 12-month price targets. The average target is $172.6, accompanied by a high estimate of $185.00 and a low estimate of $161.00. A 8.8% drop is evident in the current average compared to the previous average price target of $189.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1742994091_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Tenet Healthcare by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$161.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenet Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Tenet Healthcare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Discovering Tenet Healthcare: A Closer Look</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Key Indicators: Tenet Healthcare's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Tenet Healthcare's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -5.71% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tenet Healthcare's net margin is impressive, surpassing industry averages. With a net margin of 6.27%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Tenet Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of 7.95%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Tenet Healthcare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.09%, the company showcases efficient use of assets and strong financial health.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below the industry average at 3.16, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Tenet Healthcare: What You Need To Know

Morgan Stanley analyst Craig Hettenbach initiates coverage on Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight rating and announces Price Target of $165.

Price Target

Morgan Stanley Initiates Coverage On Tenet Healthcare with Overweight Rating, Announces Price Target of $165

WIIM

ENSG

UHAL

Shares of hospital an healthcare stocks are trading lower amid concerns over Medicaid an Medicare cuts. Additionally, President Trump recently signed an executive order on healthcare price transparency.

Across the recent three months, 8 analysts have shared their insights on Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.75, with a high estimate of $195.00 and a low estimate of $140.00. This current average has decreased by 12.18% from the previous average price target of $193.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1739469619_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Tenet Healthcare is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$161.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Benjamin Rossi</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenet Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Tenet Healthcare's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tenet Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>About Tenet Healthcare</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Financial Insights: Tenet Healthcare</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Tenet Healthcare showcased positive performance, achieving a revenue growth rate of 1.11% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.22%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Tenet Healthcare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.92% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.61%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below the industry average. With a ratio of 3.36, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Tenet Healthcare: 8 Analysts Share Their Views

Cantor Fitzgerald analyst Sarah James reiterates Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and maintains $177 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Tenet Healthcare, Maintains $177 Price Target

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and lowers the price target from $190 to $161.

Barclays Maintains Overweight on Tenet Healthcare, Lowers Price Target to $161

Whales with a lot of money to spend have taken a noticeably bearish stance on Tenet Healthcare.
Looking at options history for Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 44% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $451,318 and 2, calls, for a total amount of $70,520.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $140.0 for Tenet Healthcare during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Tenet Healthcare's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Tenet Healthcare's substantial trades, within a strike price spectrum from $130.0 to $140.0 over the preceding 30 days.
<h3>Tenet Healthcare Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739375169_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.3</td>
<td>$11.5</td>
<td>$11.82</td>
<td>$140.00</td>
<td>$83.0K</td>
<td align="right">521</td>
<td align="right">70</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$12.7</td>
<td>$11.6</td>
<td>$12.06</td>
<td>$140.00</td>
<td>$82.4K</td>
<td align="right">521</td>
<td align="right">72</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$9.2</td>
<td>$8.4</td>
<td>$8.75</td>
<td>$140.00</td>
<td>$61.0K</td>
<td align="right">426</td>
<td align="right">172</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$9.0</td>
<td>$8.3</td>
<td>$8.57</td>
<td>$135.00</td>
<td>$60.3K</td>
<td align="right">612</td>
<td align="right">171</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$9.4</td>
<td>$8.3</td>
<td>$8.81</td>
<td>$135.00</td>
<td>$60.3K</td>
<td align="right">612</td>
<td align="right">173</td>
</tr>
</tbody>
</table>

<h3>About Tenet Healthcare</h3>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
In light of the recent options history for Tenet Healthcare, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Tenet Healthcare Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,157,418, with THC's price down by -6.25%, positioned at $130.16.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Tenet Healthcare, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Smart Money Is Betting Big In THC Options

Tenet Healthcare shares are trading lower after the company reported worse-than-expected Q4 revenue results and issued FY25 net operating revenue guidance below estimates.

2025 Outlook1
Tenet's Outlook for full year 2025 (consolidated and by segment) follows.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">CONSOLIDATED ($ in millions, except per share amounts)</td>
<td colspan="1" rowspan="1">FY 2025 Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net operating revenues</td>
<td colspan="1" rowspan="1">$20,600 to $21,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income available to Tenet common stockholders</td>
<td colspan="1" rowspan="1">$1,040 to $1,185</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$3,975 to $4,175</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA margin</td>
<td colspan="1" rowspan="1">19.3% to 19.9%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted income per common share</td>
<td colspan="1" rowspan="1">$10.95 to $12.47</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted net income</td>
<td colspan="1" rowspan="1">$1,115 to $1,220</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted diluted earnings per share</td>
<td colspan="1" rowspan="1">$11.74 to $12.84</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Equity in earnings of unconsolidated affiliates</td>
<td colspan="1" rowspan="1">$265 to $275</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and amortization</td>
<td colspan="1" rowspan="1">$805 to $835</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest expense</td>
<td colspan="1" rowspan="1">$795 to $805</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Income tax expense5</td>
<td colspan="1" rowspan="1">$420 to $465</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income available to NCI</td>
<td colspan="1" rowspan="1">$910 to $960</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Weighted average diluted common shares</td>
<td colspan="1" rowspan="1">~95 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net cash provided by operating activities</td>
<td colspan="1" rowspan="1">$2,500 to $2,850</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted net cash provided by operating activities</td>
<td colspan="1" rowspan="1">$2,600 to $2,900</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">$700 to $800</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free cash flow</td>
<td colspan="1" rowspan="1">$1,800 to $2,050</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted free cash flow</td>
<td colspan="1" rowspan="1">$1,900 to $2,100</td>
</tr>
<tr>
<td colspan="1" rowspan="1">NCI cash distributions</td>
<td colspan="1" rowspan="1">$750 to $800</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Ambulatory Segment($ in millions)</td>
<td colspan="1" rowspan="1">FY 2025 Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net operating revenues</td>
<td colspan="1" rowspan="1">$4,850 to $5,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$1,915 to $1,985</td>
</tr>
<tr>
<td colspan="1" rowspan="1">NCI</td>
<td colspan="1" rowspan="1">$760 to $790</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA less NCI</td>
<td colspan="1" rowspan="1">$1,155 to $1,195</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Changes versus prior year6:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Same-facility system-wide revenue</td>
<td colspan="1" rowspan="1">Up 3.0% to 6.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Hospital Segment ($ in millions)</td>
<td colspan="1" rowspan="1">FY 2025 Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net operating revenues</td>
<td colspan="1" rowspan="1">$15,750 to $16,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$2,060 to $2,190</td>
</tr>
<tr>
<td colspan="1" rowspan="1">NCI</td>
<td colspan="1" rowspan="1">$150 to $170</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Changes versus prior year6:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Inpatient admissions</td>
<td colspan="1" rowspan="1">Up 2.0% to 3.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted admissions</td>
<td colspan="1" rowspan="1">Up 2.0% to 3.0%</td>
</tr>
</tbody>
</table>
</figure>

Earnings

Guidance

Health Care

General

Tenet Healthcare Forecasts FY2025 Net Operating Revenues Of $20.6B-$21B Versus Consensus Of $21.28B, With Adjusted EPS Of $11.74-$12.84 Versus Consensus Of $11.53

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) reported quarterly earnings of $3.44 per share which beat the analyst consensus estimate of $2.97 by 15.82 percent. This is a 28.36 percent increase over earnings of $2.68 per share from the same period last year. The company reported quarterly sales of $5.07 billion which missed the analyst consensus estimate of $5.17 billion by 1.89 percent. This is a 5.71 percent decrease over sales of $5.38 billion the same period last year.

Tenet Healthcare Q4 2024 Adj EPS $3.44 Beats $2.97 Estimate, Sales $5.07B Miss $5.17B Estimate

ACRE

AEIS

AEMD

ALCO

ALKS

AMWL

ASND

ASPN

ATRC

AVXL

AYTU

BIIB

BROS

BXMT

CAMT

CGNX

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$75.00</td>
<td>$39.4K</td>
<td>2.1K</td>
<td>8.1K</td>
</tr>
<tr>
<td>AHCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.00</td>
<td>$71.4K</td>
<td>0</td>
<td>4.7K</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$105.8K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$822.5K</td>
<td>495</td>
<td>258</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$81.1K</td>
<td>5.1K</td>
<td>217</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$270.00</td>
<td>$140.0K</td>
<td>355</td>
<td>200</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$390.00</td>
<td>$39.6K</td>
<td>484</td>
<td>151</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$610.00</td>
<td>$53.0K</td>
<td>100</td>
<td>137</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$67.50</td>
<td>$33.6K</td>
<td>1.8K</td>
<td>120</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$860.00</td>
<td>$25.3K</td>
<td>50</td>
<td>112</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 3 day(s) on February 14, 2025. This event was a transfer of 200 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $39.4K, with a price of $197.0 per contract. There were 2192 open contracts at this strike prior to today, and today 8123 contract(s) were bought and sold. 
• Regarding AHCO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>), we observe a put option sweep with bearish sentiment. It expires in 220 day(s) on September 19, 2025. Parties traded 476 contract(s) at a $10.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $71.4K, with a price of $150.0 per contract. There were 0 open contracts at this strike prior to today, and today 4752 contract(s) were bought and sold. 
• For THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we notice a call option sweep that happens to be neutral, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 300 contract(s) at a $145.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $105.8K, with a price of $355.0 per contract. There were 1108 open contracts at this strike prior to today, and today 1040 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a call option trade with bearish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $230.00 strike. The total cost received by the writing party (or parties) was $822.5K, with a price of $3290.0 per contract. There were 495 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 100 contract(s) at a $35.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $812.0 per contract. There were 5109 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option trade that happens to be bullish, expiring in 129 day(s) on June 20, 2025. This event was a transfer of 200 contract(s) at a $270.00 strike. The total cost received by the writing party (or parties) was $140.0K, with a price of $700.0 per contract. There were 355 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 99 contract(s) at a $390.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $39.6K, with a price of $400.0 per contract. There were 484 open contracts at this strike prior to today, and today 151 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on February 28, 2025. This event was a transfer of 53 contract(s) at a $610.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $53.0K, with a price of $1000.0 per contract. There were 100 open contracts at this strike prior to today, and today 137 contract(s) were bought and sold. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 65 day(s) on April 17, 2025. Parties traded 57 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $590.0 per contract. There were 1841 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bearish, expiring in 157 day(s) on July 18, 2025. This event was a transfer of 4 contract(s) at a $860.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $6340.0 per contract. There were 50 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AHCO

AMGN

MRNA

10 Health Care Stocks With Whale Alerts In Today's Session

A nationwide lockout of federal health payment systems, reportedly due to an &#8220;outage&#8221;, has led to widespread criticism of the White House. The lockout affected several organizations and agencies, including state Medicaid programs, federally funded Head Start early education programs, and community health centers.
What Happened: The White House attributed the lockout to an &#8220;outage.&#8221; White House Press Secretary Karoline Leavitt said on X that the administration is &#8220;aware&#8221; of the Medicaid website not functioning.
&#8220;We have confirmed no payments have been affected — they are still being processed and sent,&#8221; said Leavitt.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The White House is aware of the Medicaid website portal outage. We have confirmed no payments have been affected — they are still being processed and sent. We expect the portal will be back online shortly.
&mdash; Karoline Leavitt (@PressSec) <a href="https://twitter.com/PressSec/status/1884329868030271759?ref_src=twsrc%5Etfw">January 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The lockout prevented multiple state Medicaid programs from accessing their payment systems. However, operations resumed later the same day, according to a CBS News <a href="https://www.cbsnews.com/news/medicaid-head-start-health-centers-trump-funding-freeze/">report</a>. The incident coincided with President Donald Trump&#8217;s controversial decision to freeze spending across the federal government, leading to heightened criticism from state governments, nonprofits, and lawmakers.
The entities affected were unable to access the Payment Management Services web portal, run by the Department of Health and Human Services (HHS), which processes billions of dollars in payments annually. 
The lockout and the ongoing communication &#8220;pause&#8221; imposed by the Trump administration at HHS led to a flurry of requests for comment from various stakeholders, including the National Association of Medicaid Directors and several lawmakers.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43293219/teslas-30k-ev-risks-being-a-nothing-burger-says-gary-black-warns-of-cannibalization-without-a-new-compact-design">Tesla&#8217;s $30K EV Risks Being A &#8216;Nothing Burger,&#8217; Says Gary Black—Warns Of Cannibalization Without A New Compact Design</a>
Why It Matters: The lockout occurred amidst the administration&#8217;s decision to freeze spending across the federal government, a move that has been challenged legally. A federal judge issued a <a href="https://www.benzinga.com/government/regulations/25/01/43292056/judge-blocks-trumps-order-to-freeze-federal-grant-money">temporary stay on the funding freeze</a>, halting the move until further arguments can be heard.
The freeze put<a href="https://www.benzinga.com/25/01/43290381/trumps-federal-spending-freeze-puts-3-trillion-in-limbo-threatens-industries-like-clean-energy-defense-healthcare"> $3 trillion in funding under scrutiny</a>. This directive required all federal agencies to halt disbursements while programs were reviewed for alignment with Trump&#8217;s policy priorities.
The move is expected to hit sectors such as healthcare, education, clean energy and others. Stocks of clean energy companies like Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>). and Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) suffered a downturn. Shares of healthcare-sector firms like Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) and Tenet Healthcare Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) also were in the red on Tuesday.
Photo Courtesy: Shutterstock.com
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43293715/cathie-wood-dumps-tesla-stock-ahead-of-q4-earnings-ark-invest-loads-up-on-amazon">Cathie Wood Dumps Tesla Stock Ahead Of Q4 Earnings, Ark Invest Loads Up On Amazon</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

NOVA

Trump White House Blames 'Outage' For Medicaid Website Lockout: 'We Have Confirmed No Payments Have Been Affected'

The White House has ordered a temporary freeze on all federal grants and loans, putting $3 trillion in funding under scrutiny and setting the stage for a legal and political showdown over the congressional power of the purse that could heavily impact a <a href="https://www.benzinga.com/markets">wide range of industries.</a>
The directive, issued Monday by the Office of Management and Budget and received by several media outlets, requires all federal agencies to halt disbursements while programs are reviewed for alignment with President Donald Trump's policy priorities.
This includes halting new awards, existing payment and funding for projects until reviewed.
The exact financial impact of the order remains uncertain. Budget experts cited <a href="https://www.washingtonpost.com/business/2025/01/28/trump-spending-freeze-upends-washington-triggering-legal-threats-delays/">by the Washington Post </a>estimate at least tens of billions of dollars are at stake, though the White House directive suggests the total could be significantly higher.
Of the almost $10 trillion spent by the federal government in fiscal 2024, more than $3 trillion was federal financial assistance, Matthew Vaeth, acting director at the OMB, said in the memorandum.
&#8220;Financial assistance should be dedicated to advancing Administration priorities,&#8221; Vaeth said, adding that &#8220;the use of Federal resources to advance Marxist equity, transgenderism, and green new deal social engineering policies is a waste of taxpayer dollars that does not improve the day-to-day lives of those we serve.&#8221;
The White House said that Social Security and Medicare remain untouched. The sweeping pause threatens funding for universities, nonprofits, contractors and private companies that depend on federal assistance.
&#8220;Nothing in this memo should be construed to impact Medicare or Social Security benefits,&#8221; the memo said. 
The immediate focus will be on how agencies handle exemptions. The OMB memo allows federal departments to request case-by-case approvals, which means some funding may still flow, but the process is likely to be slow and politically charged.
Federal agencies have until Feb. 10, 2025, to provide OMB with detailed reports outlining which programs, projects, and activities are affected by the funding pause.
<h3 class="wp-block-heading">Legal, Political Showdown Over Federal Funds </h3>
The move is triggering legal challenges from nonprofits and Democratic-led states.
Within hours of the announcement, lawsuits were filed in federal courts in New York, Illinois and Oregon, arguing that Trump does not have the authority to withhold congressionally approved spending.
Senate Minority Leader Chuck Schumer was among the first to push back, saying Congress-approved investments are legally mandated and asserting the president lacks the authority to override the Impoundment Control Act of 1974, which restricts unilateral executive control over federal funds.
Trump has long argued that the 1974 law is unconstitutional, stating that past presidents had far more discretion over spending before its passage.
<h3 class="wp-block-heading">Which Industries Could Face Trouble?</h3>
Some of the hardest-hit sectors could include clean energy, defense, health care and education, where federal dollars have played a crucial role in driving investment and growth in recent years.
Trump's OMB memo explicitly targeted climate initiatives and green energy programs. Shares of solar and renewable energy companies were among the hardest hit following the federal funding freeze.
The Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) and the Invesco Wilderhill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>) fell by 2% and 1.3%, respectively, on Tuesday. 
Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) dropped 12%, Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 9.2% and SolarEdge Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) declined 5%. 
Defense contractors such as Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) may also see rising uncertainty. While military spending is unlikely to be cut outright, several defense contractors rely on federal grants for research and development. 
The impact on health care remains unclear. While Medicare is shielded, Medicaid funding — which supports hospitals, managed care providers and pharmaceutical companies — could be at risk.
HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) fell by 1% and 1.4%, respectively, while Tenet Healthcare Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) showed resilience Tuesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43281252/fed-set-to-signal-no-rush-to-cut-rates-as-wall-street-awaits-policy-clarity">Fed Set To Signal No Rush To Cut Rates As Wall Street Awaits Policy Clarity</a></li>
</ul>
Photo via Shutterstock.

Equities

Government

Large Cap

Regulations

Sector ETFs

Econ #s

Movers

ETFs

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

SEDG

Trump's Federal Spending Freeze Puts $3 Trillion In Limbo, Threatens Industries Like Clean Energy, Defense, Health Care

Tenet Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) short percent of float has risen 33.42% since its last report. The company recently reported that it has 3.58 million shares sold short, which is 4.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tenet Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736883015_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tenet Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tenet Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tenet Healthcare's peer group average for short interest as a percentage of float is 5.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(THC) - Analyzing Tenet Healthcare's Short Interest

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) has outperformed the market over the past 5 years by 16.42% on an annualized basis producing an average annual return of 28.9%. Currently, Tenet Healthcare has a market capitalization of $12.36 billion. 
Buying $1000 In THC: If an investor had bought $1000 of THC stock 5 years ago, it would be worth $3,566.42 today based on a price of $130.00 for THC at the time of writing.
<h3>Tenet Healthcare's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736434812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Tenet Healthcare 5 Years Ago Would Be Worth Today

16 analysts have shared their evaluations of Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $184.56, with a high estimate of $217.00 and a low estimate of $140.00. A 0.2% drop is evident in the current average compared to the previous average price target of $184.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1736272841_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Tenet Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Benjamin Rossi</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$196.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Tenet Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tenet Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Discovering Tenet Healthcare: A Closer Look</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Tenet Healthcare's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Tenet Healthcare displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 1.11%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tenet Healthcare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 12.92%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.61%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 3.36, Tenet Healthcare adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Tenet Healthcare: 16 Analysts Share Their Views

Keybanc analyst Tim Rezvan maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and lowers the price target from $200 to $185.

Keybanc Maintains Overweight on Tenet Healthcare, Lowers Price Target to $185

Truist Securities analyst David Macdonald maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and lowers the price target from $190 to $175.

Truist Securities Maintains Buy on Tenet Healthcare, Lowers Price Target to $175

Press Releases

Tenet Healthcare to Sell Five Birmingham Hospitals to Orlando Health

Tenet to Participate in the 2024 Wells Fargo Healthcare Conference

Tenet Completes Sale of Five Hospitals in Birmingham

Tenet to Report its Third Quarter 2024 Results on October 29th

Tenet to Participate in the UBS Global Healthcare Conference

Tenet Reports Strong Third Quarter 2024 Results; Raises 2024 Financial Outlook

Commure to Deploy Ambient AI Platform to Tenet Physician Resources for Enhanced Clinical Workflows

Tenet to Report its Fourth Quarter 2024 Results on February 12th

Tenet Reports Strong Fourth Quarter and FY 2024 Results; Provides 2025 Financial Outlook

Comments

Tenet Healthcare

Noticias

Últimas noticias sobre Tenet Healthcare (NYSE:THC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL